person · Reporting owner

Aromando Andrew

Disclosed activity across 3 companies

Tapewire entity: 41896
SEC CIK: 0001976455

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Ambrx Biopharma Inc.AMAM · Entity 109604	Chief Operating Officer	July 05, 2023	July 07, 2023
ONCOLYTICS BIOTECH INCONCY · Entity 6721	Chief Business Officer	June 01, 2026	June 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Ambrx Biopharma Inc.

Report date July 05, 2023 · Filed July 07, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2033-07-05	Direct	389,000	Reported balance After 2023-07-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-07-05 · Grant · Acquired 389,000 · Balance 389,000 F1: The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: 1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date. F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

F2: 1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date.

F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer.

ONCOLYTICS BIOTECH INC

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2036-06-01	Direct	260,000	Reported balance After 2026-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-01 · Grant · Acquired 260,000 · Balance 260,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Ambrx Biopharma, Inc.

Report date March 07, 2024 · Filed March 07, 2024

Section 16 reporting ended · disclosed 2024-03-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2024-03-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-03-07 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F3: These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.66 · Expires 2033-04-27	Direct	Reported balance After 2024-03-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-07 · Disposition to issuer · Disposed 371,428 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F5: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest as follows: (i) twenty-five (25) percent of the Company Common Stock vests on April 28, 2024, and (ii) the remainder vests in thirty-six equal monthly installments following such date.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.66 · Expires 2033-07-05	Direct	Reported balance After 2024-03-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-07 · Disposition to issuer · Disposed 55,570 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F7: The Company Common Stock subject to the Company Options vest as follows: (i) 1/6 of the Company Common Stock vested on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J.

F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock").

F3: These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter.

F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU.

F5: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest as follows: (i) twenty-five (25) percent of the Company Common Stock vests on April 28, 2024, and (ii) the remainder vests in thirty-six equal monthly installments following such date.

F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.

F7: The Company Common Stock subject to the Company Options vest as follows: (i) 1/6 of the Company Common Stock vested on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2026 Filed Jun 3, 2026 20:30 UTC	ONCOLYTICS BIOTECH INC ONCY · Entity 6721	GrantStock Option · Derivative	260,000	$0.00 Strike: $1.06	$0.00	Disclosure SEC source: 0001493152-26-027088 · ownership.xml · derivative · entry 1 Aromando Andrew · CIK 0001976455 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Shares · 260,000 shares Expires 2036-06-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2 · derivative.exercise_date: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. Read SEC document
February 11, 2026 Filed Feb 13, 2026 12:00 UTC	ONCOLYTICS BIOTECH INC ONCY · Entity 6721	PurchaseCommon Shares	29,600	$0.86	$25,417.52	Disclosure SEC source: 0001493152-26-006541 · ownership.xml · nonDerivative · entry 1 Aromando Andrew · CIK 0001976455 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,100 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document
March 07, 2024 Filed Mar 7, 2024 17:43 UTC	Ambrx Biopharma, Inc. AMAM · Entity 93373	Disposition to issuerOption to Purchase Common Stock · Derivative	55,570	Not disclosed Strike: $16.66	Not disclosed	Disclosure SEC source: 0000950170-24-028186 · ownership.xml · derivative · entry 3 Aromando Andrew · CIK 0001976455 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,570 shares Expires 2033-07-05 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F7 · derivative.exercise_date: The Company Common Stock subject to the Company Options vest as follows: (i) 1/6 of the Company Common Stock vested on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date. Read SEC document
March 07, 2024 Filed Mar 7, 2024 17:43 UTC	Ambrx Biopharma, Inc. AMAM · Entity 93373	Disposition to issuerOption to Purchase Common Stock · Derivative	371,428	Not disclosed Strike: $9.66	Not disclosed	Disclosure SEC source: 0000950170-24-028186 · ownership.xml · derivative · entry 2 Aromando Andrew · CIK 0001976455 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 371,428 shares Expires 2033-04-27 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F5 · derivative.exercise_date: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest as follows: (i) twenty-five (25) percent of the Company Common Stock vests on April 28, 2024, and (ii) the remainder vests in thirty-six equal monthly installments following such date. Read SEC document
March 07, 2024 Filed Mar 7, 2024 17:43 UTC	Ambrx Biopharma, Inc. AMAM · Entity 93373	Disposition to issuerRestricted Stock Units · Derivative	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-028186 · ownership.xml · derivative · entry 1 Aromando Andrew · CIK 0001976455 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2 · derivative.exercise_price: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F3 · derivative.exercise_date: These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter. F3 · derivative.expiration_date: These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter. Read SEC document
December 11, 2023 Filed Dec 11, 2023 17:19 UTC	Ambrx Biopharma, Inc. AMAM · Entity 93373	GrantCommon Stock	100,000	$0.00	$0.00	Disclosure SEC source: 0000950170-23-069448 · ownership.xml · nonDerivative · entry 1 Aromando Andrew · CIK 0001976455 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,263 F1 · security: Represents Restricted Stock Units ("RSUs") payable in common stock of the Issuer granted to the Reporting Person on December 11, 2023 (the "Grant Date"). These RSUs were granted in connection with the completion of the year-end review process and will be issued pursuant to the Company's Amended and Restated 2021 Equity Incentive Plan. F2 · shares: The RSUs will vest over thirty-six (36) months as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the Grant Date, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter. Read SEC document
July 05, 2023 Filed Jul 7, 2023 16:05 UTC	Ambrx Biopharma Inc. AMAM · Entity 109604	GrantStock Option (right to buy) · Derivative	389,000	$0.00 Strike: $2.38	$0.00	Disclosure SEC source: 0000950170-23-032229 · ownership.xml · derivative · entry 1 Aromando Andrew · CIK 0001976455 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,000 Underlying: Ordinary Shares · 389,000 shares Expires 2033-07-05 F1 · derivative.exercise_price: The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: 1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date. F3 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document
April 28, 2023 Filed May 5, 2023 16:10 UTC	Ambrx Biopharma Inc. AMAM · Entity 109604	GrantStock Option (right to buy) · Derivative	2,600,000	$0.00 Strike: $1.38	$0.00	Disclosure SEC source: 0000899243-23-012347 · doc4.xml · derivative · entry 1 Aromando Andrew · CIK 0001976455 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,600,000 Underlying: Ordinary Shares · 2,600,000 shares Expires 2033-04-28 F1 · derivative.exercise_price: The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · kind: Grant awarded as an inducement grant in connection with the Reporting Person's appointment as Chief Operating Officer of the Issuer. F3 · derivative.exercise_date: Twenty-five percent of the Ordinary Shares subject to the option vested on April 28, 2024, and the remainder vests in thirty-six equal monthly installments following such date. F4 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.